DOCS — Stock Film
STOCK FILMSCENE 1/11DOCS · $25.61
Stock Expert AI presents
DOCS
Doximity, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Doximity, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 880 employees. Now — the numbers.

on the stock market since 2021
880 employees
$3.8B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $30 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 30%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
94%Subscription
Subscription 94%Service, Other 6%
94% of all revenue comes from a single line: Subscription.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 17% a year over the last 4 years. Every year shown ended in profit.

$343.5M
2022
$419.1M
2023
$475.4M
2024
$570.4M
2025
$644.9M
2026
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
96
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
93
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
71
strong

Clearly above the class average — a step short of the very top.

GROWTH
86
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
35
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 30% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 15% a year on average.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $748.6M in the vault; even if every debt were paid off, $738.4M would remain.

1
THE RISKS · 1/2
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 35/100. For a turnaround signal, the stock first needs to close the gap with the market.

2
THE RISKS · 2/2
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, DOCS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: DOCS is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film